These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 36995891)

  • 1. Approach to the Patient: The Evaluation and Management of Men ≥50 Years With Low Serum Testosterone Concentration.
    Grossmann M; Jayasena CN; Anawalt BD
    J Clin Endocrinol Metab; 2023 Aug; 108(9):e871-e884. PubMed ID: 36995891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late-onset hypogonadism: metabolic impact.
    Grossmann M; Ng Tang Fui M; Cheung AS
    Andrology; 2020 Nov; 8(6):1519-1529. PubMed ID: 31502758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypotestosteronaemia in the aging male: should we treat it?
    Christe N; Meier CA
    Swiss Med Wkly; 2015; 145():w14216. PubMed ID: 26599486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-related testosterone decline is due to waning of both testicular and hypothalamic-pituitary function.
    Golan R; Scovell JM; Ramasamy R
    Aging Male; 2015; 18(3):201-4. PubMed ID: 26075536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
    Bhasin S; Brito JP; Cunningham GR; Hayes FJ; Hodis HN; Matsumoto AM; Snyder PJ; Swerdloff RS; Wu FC; Yialamas MA
    J Clin Endocrinol Metab; 2018 May; 103(5):1715-1744. PubMed ID: 29562364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy.
    Yeap BB; Grossmann M; McLachlan RI; Handelsman DJ; Wittert GA; Conway AJ; Stuckey BG; Lording DW; Allan CA; Zajac JD; Burger HG
    Med J Aust; 2016 Aug; 205(4):173-8. PubMed ID: 27510348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional hypogonadism in middle-aged and older men: testosterone treatment or not?
    Grossmann M; Jones TH
    Eur J Endocrinol; 2021 Aug; 185(3):D1-D9. PubMed ID: 34260411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testosterone therapy in older men: clinical implications of recent landmark trials.
    Grossmann M; Anawalt BD; Yeap BB
    Eur J Endocrinol; 2024 Jul; 191(1):R22-R31. PubMed ID: 38917356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment and management of male androgen disorders: an update.
    Chan I; Fui MN; Zajac JD; Grossmann M
    Aust Fam Physician; 2014 May; 43(5):277-82. PubMed ID: 24791767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testosterone deficiency in men with Type 2 diabetes: pathophysiology and treatment.
    Gianatti EJ; Grossmann M
    Diabet Med; 2020 Feb; 37(2):174-186. PubMed ID: 31006133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testosterone replacement in men.
    Beg S; Al-Khoury L; Cunningham GR
    Curr Opin Endocrinol Diabetes Obes; 2008 Aug; 15(4):364-70. PubMed ID: 18594278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Declining testicular function in aging men.
    Tenover JS
    Int J Impot Res; 2003 Aug; 15 Suppl 4():S3-8. PubMed ID: 12934044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone replacement therapy: For whom, when and how?
    Tsametis CP; Isidori AM
    Metabolism; 2018 Sep; 86():69-78. PubMed ID: 29530796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale.
    Lunenfeld B; Saad F; Hoesl CE
    Aging Male; 2005 Jun; 8(2):59-74. PubMed ID: 16096160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feedback inhibition of gonadotropins by testosterone in men with hypogonadotropic hypogonadism: comparison to the intact pituitary-testicular axis in primary hypogonadism.
    Shimon I; Lubina A; Gorfine M; Ilany J
    J Androl; 2006; 27(3):358-64. PubMed ID: 16474013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testosterone administration in older men.
    Matsumoto AM
    Endocrinol Metab Clin North Am; 2013 Jun; 42(2):271-86. PubMed ID: 23702401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aging and androgens: Physiology and clinical implications.
    Anawalt BD; Matsumoto AM
    Rev Endocr Metab Disord; 2022 Dec; 23(6):1123-1137. PubMed ID: 36459352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testosterone replacement therapy for late-onset hypogonadism.
    Cunningham GR
    Nat Clin Pract Urol; 2006 May; 3(5):260-7. PubMed ID: 16691239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of testosterone replacement therapy in men with age-dependent hypogonadism on body composition, and serum levels of leptin, adiponectin, and C-reactive protein.
    Dudek P; Kozakowski J; Zgliczyński W
    Endokrynol Pol; 2020; 71(5):382-387. PubMed ID: 32797473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen deficiency in the aging male: when to evaluate and when to treat.
    Nolten WE
    Curr Urol Rep; 2000 Dec; 1(4):313-9. PubMed ID: 12084310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.